Spirogen is a member of the AstraZeneca group. We have developed a potent and flexible class of ADC payload based on our proprietary PBD technology.
PBD payloads have been clinically validated in multiple partnered programs.
We have developed a third generation of PBD payload with marked improvements in terms of activity, ease of manufacture, therapeutic index and available quality control assays.
We collaborate closely with licensors of the PBD ADC technology, providing expertise in the selection of the optimal payload for a particular application.